[Expert consensus on the long-term management of gonadotropin-releasing hormone agonists in premenopausal patients with hormone receptor-positive breast cancer (2026 edition)]
{{output}}
Compared with postmenopausal patients, premenopausal patients with hormone receptor-positive (HR+) breast cancer generally exhibit higher tumor heterogeneity, greater invasiveness and a poorer prognosis, with a 5-year postoperative recurrence rate of 20%-30%. ... ...
